Author

C. Llorca

Institution: Hospital General de Elda

Observed institutions: Universitat Autònoma de Barcelona, Hospital Universitari i Politècnic La Fe, Hospital Son Llatzer, Hospital de Basurto, Centro Oncológico de Galicia, Hospital General Universitario de Elche, Vall d'Hebron Hospital Universitari, Hospital Universitario Puerto Real, Hospital General de Elda, Hospital General San Jorge, Complejo Hospitalario de Ourense, Hospital Universitario de Jerez

OpenAlex ID: A5111421007

Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients

1996 · J. Aparicio, A. Oltra, et al. · European Journal of Cancer · 22

3019 Current practice of prophylaxis with granulocyte colony-stimulating factors for preventing chemotherapy-induced neutropenia in breast cancer patients in Spain

2009 · J. Marina, F.J. Carabantes, et al. · European Journal of Cancer Supplements · 4

Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment for patients with metastatic breast cancer

2004 · C. Llorca, J. Mayordomo, et al. · Journal of Clinical Oncology · 3

Observational transversal study to relate functional status and age with the doublet or triplet chemotherapy based on capecitabine in advanced gastric cancer patients.

2011 · B. Martinez Amores, M. Alsina, et al. · Journal of Clinical Oncology · 1

11P Molecular profiling and targeted therapy in cholangiocarcinoma

2020 · M. García Pardo de Santayana, L. Ortega, et al. · Annals of Oncology

Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial

2017 · A. Fernández, M. Salgado, et al. · Annals of Oncology

Prognostic Factors Influencing the Selection of Bevacizumab Combined With Chemotherapy in Patients With HER2-Negative Metastatic Breast Cancer in Routine Clinical Practice. Oncosur-Avalox: Observational Cross-Sectional Study

2012 · L. Manso, R. Perez-Carrion, et al. · Annals of Oncology

Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors: Pronost study.

2011 · G. Esquerdo, J. M. Cervera, et al. · Journal of Clinical Oncology

Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors (Pronost Study).

2010 · G. Esquerdo, J. Cervera, et al. · Journal of Clinical Oncology

1144 POSTER Comparison of two questionnaires assessing fatigue in patients with chemotherapy-induced anaemia treated with darbepoetin alfa every 3 weeks

2007 · G. Esquerdo, C. Llorca, et al. · European Journal of Cancer Supplements

An assessment of cancer-related fatigue in patients (pts) with chemotherapy-induced anaemia (CIA) treated with darbepoetin alfa (DA): Comparison of two quality of life (QoL) questionnaires

2007 · G. Esquerdo, C. Llorca, et al. · Journal of Clinical Oncology

Biweekly docetaxel and carboplatin as first line chemotherapy in advanced non small cell lung cancer (NSCLC)

2006 · J. L. Fírvida, G. Esquerdo, et al. · Journal of Clinical Oncology

Works count: 12

Citation count: 30

H-index: 3

I10-index: 1